The apoptotic pathway activated by chimeric anti-CD20 monoclonal antibodies (rituximab, IDEC.C2B8) was analyzed using the Burkitt lymphoma cell line Ramos. Crosslinking of CD20 (CD20XL) induced apoptosis in Ramos cells, which involved loss of mitochondrial membrane potential (⌬ m ), the release of cytochrome-c (cyt-c), and activation of caspases-9 and -3. Nevertheless, several lines of evidence showed that the apoptotic outcome did not depend on these events. First, under circumstances where Ramos cells display resistance to either CD95-or B cell receptor (BCR)-induced apoptosis, CD20XL-induced apoptosis was not affected, pointing to a distinct pathway. Second, the broad-spectrum caspase inhibitor zVAD-fmk prevented processing of caspase-9, -3 and PARP as well as DNA fragmentation, but did not block apoptosis as measured by annexin V staining, cell size and membrane integrity. Lastly, Bcl-2 overexpression blocked cyt-c release and the decrease in ⌬ m , and completely prevented CD95-or BCR-mediated apoptosis; however, it did not affect CD20XL-induced cell death. We conclude that although CD20XL can initiate the mitochondrial apoptosis pathway, CD20-induced apoptosis does not necessarily require active caspases and cannot be blocked by Bcl-2. Since most chemotherapeutic drugs require the activation of caspases to exert their cytotoxicity, these findings provide an important rationale for the use of CD20 mAbs in chemoresistant malignancies.
Introduction
The chimeric anti-CD20 monoclonal antibody (mAb) IDEC-C2B8 (rituximab) has become an important treatment modality in low-grade non-Hodgkin's lymphoma (NHL). 1, 2 Its application in other CD20-positive B cell malignancies, eg aggressive lymphomas, 3 post-transplant lymphoma, or chronic lymphocytic leukemia (reviewed in Refs. 4 and 5) , is rapidly expanding. It has been reported that anti-CD20 mAbs can induce apoptosis in B cell lines, 6, 7 and this effector mechanism, in addition to complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity, may very well contribute to the clinical results.
Apoptosis, or programmed cell death, is characterized by typical morphological and biochemical changes like cell shrinkage, membrane blebbing, exposure of phosphatidyl serine (PS) to the outer leaflet of the cytoplasmic membrane, chromatin condensation and DNA fragmentation. 8, 9 The exposure of PS on a dying cell is a determining factor for engulfment and phagocytosis by neighboring cells. 10 Caspases, a family of cysteine proteases that cleave their substrate after aspartidyl residues, play a crucial role during the execution of apoptosis. Caspases can be divided into initiators (caspase-2, -8, -9, -10), which exert a regulatory role during apoptosis by activating the effector caspases (caspase-3, -6, -7), which function as executioners by cleaving essential cellular and nuclear structures. 11 Two major caspase-dependent pathways leading to apoptosis have been identified: the death receptor mediated form of apoptosis, and a mitochondria-dependent pathway. 12, 13 Ligation of death receptors such as CD95 (Fas), leads to the recruitment of the initiator caspase-8 to the so-called death-inducing signaling complex (DISC). Caspase-8 activates downstream effector caspases, either directly (type I cells) or indirectly by cleaving Bid, which then induces the release of cytochrome c (cyt-c) from the mitochondria (type II cells). 14, 15 The second form of caspase-dependent apoptosis can be triggered by irradiation for example, cytotoxic drugs or via p53. These stimuli induce mitochondrial release of cyt-c that, together with apoptosis promoting factor 1 (Apaf1) recruits and activates the initiator caspase-9 in a multimeric structure termed the apoptosome. 16, 17 Caspase-9 then activates downstream effector caspases. An important aspect of the mitochondrial route of apoptosis is the sensitivity to modulation by pro-and anti-apoptotic members of the Bcl-2 family. Although the exact mechanism is currently unknown, these proteins can either induce or prevent mitochondrial damage and release of cyt c. 18, 19 The upregulation of anti-apoptotic Bcl-2 family members is considered to be an important mechanism by which malignant cells can remain viable in circumstances which would normally trigger apoptosis. 9 Recently, several studies have described caspaseindependent forms of cell death, in which caspases are either not activated, or are activated but not essential for the induction of cell death. [20] [21] [22] [23] [24] Although in these latter studies cell death was not prevented by caspase inhibitors, nuclear features of apoptosis such as large-scale chromatin condensation and oligonucleosomal DNA fragmentation disappeared, indicating that active caspases are required for these characteristic nuclear features.
The aim of the present study was to establish apoptotic pathways activated by chimeric anti-CD20 mAbs. To this end, the Burkitt lymphoma cell line Ramos was used, as well as available Ramos clones with varying sensitivities to CD95 and/or B cell receptor (BCR)-mediated apoptosis. 25 Furthermore, it was investigated whether caspases and/or the mitochondrial route of apoptosis were essential, by applying the broad-spectrum caspase inhibitor zVAD-fmk and overexpression of Bcl-2, respectively. The major finding is that although mitochondrial triggering and caspase activation do take place upon CD20XL, these events are not obligatory for cells to become apoptotic.
Materials and methods

Antibodies and reagents
Chimeric CD20 mAbs (IDEC-C2B8, rituximab) were supplied by Roche Nederland BV (Mijdrecht, The Netherlands). Fas10 mAbs and Fas2 mAbs (stimulating and blocking antibodies to the CD95 receptor, respectively) were a kind gift from Prof Dr L Aarden (CLB Sanquin Blood Supply Foundation, Amsterdam, The Netherlands). Anti-human IgM mAbs (CLB/MH15) and CD40 mAbs (CLB-CD40/1, clone 14G7) were obtained from the CLB Sanquin Blood Supply Foundation (CLB, Amsterdam, The Netherlands). Goat anti-human IgG (Fc␥-fragment specific) was used as crosslinker (Jackson ImmunoResearch Laboratories, West Grove, PA, USA). The broad-spectrum caspase inhibitor zVAD-fmk (O-methylated form to enable cell entry) was obtained from Alexis Biochemicals (Läuferlingen, Switzerland). FITC-labeled annexin V was from Nexins Research BV (Kattendijke, The Netherlands), propidium iodide (PI) was from Sigma Chemical (St Louis, MO, USA), and MitoTracker Orange was from Molecular Probes (Leiden, The Netherlands). The following antibodies were used in immunoblot analysis: polyclonal antibodies to caspase-3 and monoclonal antibodies to cyt-c (7H8.2C12) (Pharmingen, San Diego, CA, USA), polyclonal antibodies to caspase-8 (a kind gift from Prof Dr J Borst, The Netherlands Cancer Institute, Amsterdam, The Netherlands), monoclonal antibodies to poly (ADPribose) polymerase (PARP) (clone C-2-10, Biomol Research Laboratories, Plymouth Meeting, PA, USA), polyclonal antibodies to activated caspase-3 and -9 (New England Biolabs, Beverly, MA, USA), and monoclonal antibodies to Bcl-2 (DAKO, Glostrup, Denmark). Monoclonal antibodies detecting ␣-tubulin (55 kDa) were from Sigma. Horseradish peroxidase (HRP)-conjugated goat anti-mouse (GAM) immunoglobulins (Ig) were from the CLB, HRP-conjugated swine anti-rabbit (SwAR) Ig were from DAKO.
Cell lines
The Burkitt lymphoma cell line Ramos (obtained from the ATCC; Ramos wild type, further referred to as Ramos) as well a Ramos clone with enhanced sensitivity for apoptosis induced via either CD95 (Ramos.FSA) were used. Ramos.FSA cells transduced with a retroviral construct encoding a dominant negative form of the adapter protein FADD have been described. 25 Cells were cultured in Iscove's modified Dulbecco's medium (IMDM; Gibco Life Technologies, Paisley, UK), supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS; ICN Biomedicals, Meckenhein, Germany), 100 U/ml penicillin, 100 g/ml streptomycin and L-glutamin (Gibco).
Bcl-2 cDNA was a gift from John Reed (Burnham Institute, La Jolla, CA, USA) and cloned into the pCEP4 vector (Invitrogen, San Diego, CA, USA). Sequences were confirmed by automated sequencing. Stable Ramos transfectants were generated by electroporation, and hygromycin B-resistant clones were isolated by limiting dilution. Stable transfectants were screened by RNA blots using probes for Bcl-2 and by Western blots using anti-Bcl-2 (Ancell, Bayport, MN, USA). The Bcl-2 overexpressing Ramos cells were cultured in IMDM culture medium as described above, supplemented with hygromycin B (300 g/ml). All clones consistently displayed a comparable expression of CD95, sIgM and CD20.
Induction and detection of apoptosis
Cells were stimulated in 48-wells plates or 25 mm 2 culture flasks (0.25-1.0 × 10 6 /ml) with the indicated mAbs (5 g/ml) for 4 h (CD95) or 24 h (chimeric CD20 mAbs and anti-BCR) unless indicated otherwise. Crosslinking mAbs (final concentration 50 g/ml), CD40 mAbs (ascites dilution 1/500) and/or Fas2 mAbs (5 g/ml) were added 5 min after the indicated mAbs. The broad-spectrum caspase inhibitor zVAD-fmk (final concentration as described in results) was added 15 min before the indicated mAbs.
Phosphatidyl serine (PS) exposure on apoptotic cells was measured as described previously. 26 In brief, cells were washed in ice-cold Hepes buffer (10 
Immunoblot analysis
Lysates were prepared by suspending stimulated or unstimulated cells (±5 × 10 6 ) in lysis buffer (1% NP40, 10 mM TrisHCl pH 7.4, 150 mM NaCl, 5 mM EDTA, 1 mM tosyl-lysinechloromethyl ketone, 0.02 mg/ml ovomucoid trypsin inhibitor, 1 mM phenylmethylssulphonylfluoride (PMSF), 0.02 mg/ml leupeptin and 25 M phenylarsine oxide). Lysates were cleared by centrifugation at 13 000 g for 15 min. Protein contents in cell lysates were determined using bicinchonic acid assay 27 (BCA, Pierce, Rockford, IL, USA). Thirty to 50 g of protein/lane was separated by SDS-PAGE under reducing conditions. After transfer on to nitrocellulose or PVDF membranes (Hybond-C and Hybond-P respectively, Amersham, Buckinghamshire, UK), blots were blocked with 5% non-fat dry milk in TBST (10 mM Tris, 150 mM NaCl and 0.05% Tween-20, pH 8.0), and were probed with the indicated antibodies diluted in TBST containing 2.5% non-fat dry milk. Immunoreactive proteins were visualized using HRP-conjugated Ig (GAM or SwAR) and enhanced chemiluminescence (ECL, Amersham).
Preparation of cytosolic cell extracts for analysis of cyt-c release
Cells (5.0 × 10 6 per sample) were washed twice in ice-cold PBS and resuspended in 100 l of extraction buffer (50 mM PIPES-KOH pH 7.4, 220 mM mannitol, 68 mM sucrose, 50 mM KCl, 5 mM EGTA, 2 mM MgCl 2 , 1 mM dithiothreitol and the protease inhibitors leupeptin, trypsin-inhibitor and PMSF, concentrations as described for NP40 lysis buffer) and allowed to swell on ice for 30 min. This was followed by incubation with digitonin (final concentration 200 g/ml) for 15 min at 4°C. Lysates were centrifuged at 13 000 g for 15 min and supernatants were harvested and stored at −20°C until use. 28 DNA strand breaks were detected using the APO-DIRECT Kit (Phoenix Flow Systems, San Diego, CA, USA). In brief, cells (1.0 × 10 6 ) were washed in PBS, fixed in 1% paraformaldehyde, and permeabilized in 70% ethanol. Fluoresceintagged dUTP was coupled to the DNA strand breaks using terminal deoxynucleotidyl transferase (TdT).
Analysis of DNA fragmentation by TUNEL assay
Evaluation of mitochondrial membrane potential (⌬ m )
MitoTracker Orange (CMTMRos) was used according to the manufacturer's recommendations. A decrease in MitoTracker fluorescence is considered to be a measure for loss of ⌬ m .
14 Cells (0.25 × 10 6 /ml) were incubated with MitoTracker (final concentration 200 nM) for 30 min at 37°C, washed twice in Hepes buffer, and double-stained with FITC-labeled annexin V (as described above) and immediately analyzed on a FACS-scan.
Electron microscopy
5 × 10 6 stimulated cells were pelleted and fixed in 1% glutaraldehyde, and postfixed in 1% osmium tetraoxid (10 min) followed by 1% uranyl acetate (5 min). Samples were dehydrated with 2 changes of 2,2-dimethyoxypropane at RT and after 1 h impregnation with DMP/EPON 1:1 and pure EPON (1 h) embedded in epoxy resin. After contrasting with uranyl acetate and Pb-citrate, the ultrathin sections were examined in a Philips CM10 electronmicroscope at a magnification of ×6100.
Results
Crosslinking of CD20 activates an apoptotic pathway distinct from CD95-or BCR-triggered apoptosis
Incubation with chimeric anti-CD20 mAbs (Rituximab, 5 g/ml) alone had no effect on Ramos cells, but crosslinking with goat anti-human IgG (further referred to as CD20XL) did induce apoptosis ( Figure 1a ). Time-course experiments showed that apoptosis, quantitated by annexin V binding to exposed phosphatidyl serine, started 4-8 h after incubation, reaching ±50% apoptotic cells after 24 h (see also below). Figure 1b shows representative EM images of untreated cells and cells with crosslinked CD20. Treated cells have increased electron density and display typical hallmarks of apoptosis such as reduced size and pyknotic nuclei with extremely condensed chromatin. Cytoplasmic organelles such as mitochondria, ER and Golgi were no longer visible at this stage. Apoptotic cells stimulated with ␣CD95-or ␣BCR-mAbs looked similar (not shown). A first clue that distinguished CD20XL-induced apoptosis emerged when it was compared to established models of CD95-and BCR-mediated cell death. Antagonistic antibodies to the CD95 receptor (Fas2 mAb) completely inhibited CD95-induced apoptosis in Ramos, but did not affect CD20XL-induced apoptosis (Figure 2a ). The effect of CD20XL was then examined in situations with altered responses to either CD95 or BCR triggering. Ramos.FSA, which is highly sensitive to CD95-induced apoptosis, was transduced with a retroviral construct encoding a dominant negative (DN) form of the adapter protein FADD. 25 Shown in Figure 2b , as expected FADD-DN blocked CD95 signalling, but it did not influence BCR-or CD20-mediated apoptosis. When CD20XL was directly compared with BCR triggering, it was found that anti-CD40 mAbs, which are known to prevent BCR-induced apoptosis, 29 did not inhibit CD20XL-induced apoptosis (Figure 2c ). Collectively, these findings indicated that the intracellular pathway activated by CD20XL is distinct from both the CD95 and the BCR-induced apoptosis pathways.
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Figure 1
Crosslinking of CD20 induces apoptosis: PS exposure and chromatin condensation. (a) Ramos cells were untreated (left panel), or incubated for 24 h with chimeric CD20 mAbs (5 g/ml; middle), or CD20 + goat anti-human IgG (5 g/ml + 50 g/ml; right). Apoptosis was detected by binding of FITC-labeled annexin V and propidium iodide uptake as described in Materials and methods. Quadrant markers were set using the CD20 sample, percentages for each quadrant are given. Incubation with crosslinking mAbs alone did not induce apoptosis (not shown). 
CD20XL induces cytochrome c release, caspase-3 and -9 activation, and DNA fragmentation, but caspase inhibition does not prevent apoptosis
To uncover a potential point of divergence between CD20XL in comparison with CD95-or BCR-mediated apoptosis, the status of several established apoptotic parameters was monitored. During CD20XL-induced cell death caspase-3 was processed into two fragments (17 kDa and 19 kDa, Figure 3a) . Initial cleavage of the caspase-3 proform at Asp-175 (resulting in a 20 kDa product) is followed rapidly by autocatalytic cleavage at Asp-9 and Asp-28, resulting in the observed 17 kDa and 19 kDa products. 30 PARP, a DNA repair enzyme, whose cleavage by effector caspases is considered to be a hallmark of apoptosis, was also processed during CD20XL-induced apoptosis (Figure 3a) . Two important apoptotic mediators upstream of caspase-3 are shown in Figure 3b . CD20XL, as well as BCR and CD95 triggering induced the release of cyt-c and the activation of caspase-9. An important consequence of caspase-3 activation is DNA fragmentation, 31 and this could be demonstrated by TUNEL assay after all three stimuli (shown for CD20XL in Figure 4a, upper panel) . Processing of caspase-8 was also observed after CD20XL, but this occurred only subsequent to caspase-3 activation (data not shown). Hence, caspase-8 is apparently not instrumental and is most likely cleaved in a feedback loop by previously activated executioner caspases. 32, 33 Thus, CD20XL can induce the release of mitochondrial cyt-c and the activation of caspases-
Figure 2
The apoptosis-inducing pathway used by CD20XL is distinct from the pathways activated after ligation of CD95 or the BCR. Cells were treated with anti-CD95 mAbs (4 h), anti-BCR mAbs or CD20XL (both 24 h). 9 and -3, and in these aspects apparently does not differ from CD95-or BCR-induced apoptosis in Ramos cells.
We then investigated the effect of the broad-spectrum caspase inhibitor zVAD-fmk on these parameters after the various stimuli. CD20XL and BCR triggering in the presence of zVAD- fmk yielded a 20 kDa cleavage product of caspase-3, but this was not accompanied by processing of PARP (Figure 3a) . In addition, caspase-9 remained in precursor state when zVADfmk was present (Figure 3b) , as demonstrated by the absence of the 37 kDa activation product. It has been reported that caspase-9 is quite active in zymogen form, 34 and also poorly inhibited when incorporated in the apoptosome. 35, 36 Consequently, in the presence of zVAD-fmk, unprocessed caspase-9 can supply the initial cleavage of caspase-3 into a 20 kDa form, but further caspase activity is prevented. Indeed, addition of zVAD-fmk precluded PARP cleavage and TUNEL positivity in all cases (shown for CD20XL in Figure 4a ), confirming that executioner caspase activity is blocked. Since CD95-mediated apoptosis depends on the apical caspase-8, addition of zVAD-fmk was expected to prevent cyt-c release, caspase-9 and -3 activation and PARP cleavage, and this was indeed observed (Figure 3a and b) . At the level analyzed here, BCR-and CD20XL-induced apoptosis appear similar in the sense that cyt-c release is not blocked by zVAD-fmk, but caspase-3 remains inactive and cannot initiate downstream events. However, a crucial observation in relation to these findings was that in cells stimulated by CD20XL, zVAD-fmk only partially inhibited apoptosis (indicated in Figure 4a , lower panel). In the presence of zVAD-fmk, a significant fraction of CD20XL-treated cells still bound annexin V and dis- played other apoptotic features like cell shrinkage and loss of membrane integrity as measure by F/SSC and PI uptake by FACS. This response was clearly distinct from the complete block in apoptosis observed for CD95 or BCR triggering in the presence of zVAD. In addition, EM images of cells treated with CD20XL in the presence of zVAD (Figure 4b ) distinctly showed partial chromatin condensation and dissolution of the nuclear membrane. The cellular organelles appeared clustered and surrounded by membraneous structures, reminiscent of autophagic vacuoles. 37 
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Caspases and mitochondrial activation are not instrumental in CD20XL apoptosis
Further analysis then focused on the mitochondrial aspects of apoptosis and PS exposure after CD20XL. Consistently, preincubation with 200 M zVAD-fmk was unable to prevent CD20XL-induced apoptosis, as measured by annexin V staining, changes in cell size and PI uptake (Figure 5a ). Identical results were obtained when the concentration of zVAD-fmk was increased to 500 M (not shown). On average, the percentage of apoptotic cells after 24 h was 49 ± 3% in the absence of zVAD-fmk, vs 28 ± 2% in the presence of zVADfmk (n = 11). This was in sharp contrast to CD95-and BCRinduced apoptosis, which were both completely prevented by lower concentrations of zVAD-fmk (50 M and 100 M, respectively). Time-course experiments (Figure 5b ) demonstrated that CD95-and BCR-induced apoptosis remained around background levels for up to 48 h in the presence of zVAD-fmk. After CD20 triggering, however, apoptotic cells could clearly be observed from 4-8 h on, both in the presence and absence of zVAD-fmk.
Since Bcl-2 is known to block the mitochondrial route of apoptosis by preventing cyt-c release, 18, 19 the influence of Bcl-2 overexpression on CD20XL-induced apoptosis was investigated using transfected Ramos cells (Ramos.Bcl-2). The overexpression of Bcl-2 in this clone was confirmed by Western blotting (Figure 6a ). When tested for the various apoptotic stimuli, it was consistently found that Ramos.Bcl-2 cells were sensitive to CD20XL-induced apoptosis but resistant to CD95-and BCR-induced apoptosis (Figure 6b ). In the case of the Ramos.Bcl-2 clone, the addition of zVAD-fmk did not significantly diminish the apoptotic outcome after CD20XL (data not shown). Nevertheless, the release of cyt-c from the mitochondria appeared to be blocked by overexpression of Bcl-2, regardless of the stimulus (Figure 7a ). Since these results indicated that CD20XL-induced apoptosis could proceed without cyt-c release, we examined another aspect of mitochondrial damage, and monitored the inner mitochondrial transmembrane potential (⌬ m ). CD20 and BCR triggering were both accompanied by a decrease in MitoTracker fluorescence in Ramos.FSA cells (Figure 7b ), indicating loss of ⌬ m . Analogous to the findings with cyt-c release, these changes in ⌬ m were not prevented by zVAD-fmk (data not shown). In CD95-induced apoptosis a decrease in ⌬ m could not be observed until late in the process, after PS exposure had occurred. Importantly, in Ramos.Bcl-2 cells a decrease in ⌬ m was not observed after the various stimuli (Figure 7b ) but as mentioned above, CD20 triggering still caused cells to become apoptotic (percentage is indicated in Figure 7b) . Control experiments showed that Ramos.Bcl-2 cells treated with chemical uncouplers (CCCP) did respond with a drop in ⌬ m (not shown). These data indicate that high levels of Bcl-2 can also protect against loss of inner mitochondrial membrane potential, and excluded that CD20XL can specifically activate a damage pathway that utilizes dissipation of ⌬ m to trigger apoptosis.
Discussion
The main observation of the present study is that although CD20XL can lead to mitochondrial changes and caspase activation, these events are not obligatory for the relay of the apoptotic signal. The data and their interpretation may have direct relevance for the clinical application of anti-CD20
Figure 5
The broad-spectrum caspase inhibitor zVAD-fmk completely blocks CD95-or BCR-mediated apoptosis, but cannot fully prevent CD20XL-induced apoptosis. Ramos.FSA cells were incubated with anti-CD95 mAbs, anti-BCR mAbs or CD20XL in the presence or absence of zVAD-fmk (concentrations as described in legend of Figure  3 ). (a) Cells were harvested after 4 h (anti-CD95) or 24 h (CD20XL and anti-BCR) and stained with annexin V and PI. The percentage of apoptotic cells ± s.e.m. is presented (n = 11). (b) Cells were harvested at different time points and the percentage of apoptotic cells at each time point is depicted. Numbers are corrected for the spontaneous amount of apoptosis, which varied between 7 and 13% in this experiment. One representative experiment out of three is presented; after 24 h zVAD-fmk was replenished to compensate for its turnover.
Figure 6
CD20XL-induced apoptosis is not inhibited by overexpression of Bcl-2. (a) Lysates were prepared from unstimulated Ramos wild type (wt) and Ramos.Bcl-2 cells. Western blots were prepared using monoclonal anti-Bcl-2 antibodies. (b) Ramos.wt or Ramos.Bcl-2 cells were incubated with anti-CD95 mAbs, anti-BCR mAbs or CD20XL (for 24 h) and the percentage of apoptosis was measured by annexin V and PI staining. Data are mean ± s.e.m. of at least four experiments; n = 9 for the Ramos.Bcl-2 plus CD20XL data.
mAbs. In agreement with previous observations, 6 we found that chimeric anti-CD20 mAbs only induce apoptosis after crosslinking (CD20XL). Certain reports, however, do claim that CD20 mAb alone can also induce apoptosis, albeit after a long lag time. 7, 38 We have also examined a Ramos subclone which is sensitive to CD20-mediated apoptosis without crosslinking. However, this response was lost at lower concentrations of CD20 mAb, where crosslinking still triggered apoptosis (unpublished observation). Therefore, we investigated cell death dependent on crosslinking, also because it probably better reflects the situation in vivo (see also below). Antagonistic CD95-antibodies or a FADD-DN construct did not interfere with CD20XL-induced cell death. Also, cleavage of caspase-8 occurred only after active caspase-3 was detected, reflecting a feedback loop described before.
32,33
Figure 7
Overexpression of Bcl-2 prevents cytochrome c release and dissipation of ⌬ m . Taken together, these data strongly indicate that caspase-8 and/or FADD are not involved in the initiation phase upon CD20XL.
CD20XL triggered the mitochondrial release of cyt-c and loss of ⌬ m, and activation of caspase-9 and the effector caspase-3. These characteristics have also been described for BCR-induced apoptosis. 39, 40 A correlation between BCR-and CD20XL-mediated apoptosis in Burkitt lymphoma cell lines has been noted before. 41 Another similarity with BCR triggering was that CD20XL-induced loss of ⌬ m and release of cyt-c were not inhibited by the caspase inhibitor zVAD-fmk. This suggests that CD20XL can activate a mitochondrial, or 'intrinsic', pathway of apoptosis. Nevertheless, our data also clearly discriminate between CD20XL-and BCR-induced apoptosis. First, CD40 mAbs completely inhibited BCRinduced apoptosis of Ramos cells, but did not prevent Leukemia CD20XL-induced apoptosis. Second, the broad-spectrum caspase inhibitor zVAD-fmk totally prevented BCR-induced apoptosis, whereas CD20XL-induced apoptosis was only partially inhibited. Finally, BCR-induced apoptosis was blocked by Bcl-2 overexpression, but CD20XL-induced apoptosis was not. Thus, similarities between CD20XL-and BCR-induced apoptosis are evident once mitochondrial triggering takes place. The relevant distinction is that the BCR pathway depends on it, whereas CD20XL can still result in an apoptotic outcome even when mitochondrial damage and/or caspases are blocked.
The fact that the broad-spectrum caspase inhibitor zVADfmk had only a partial inhibitory effect on CD20XL-induced apoptosis was surprising. Since CD95-and BCR-mediated apoptosis were both entirely blocked at lower concentrations of zVAD-fmk, there is no doubt about the ability of the (methylated) inhibitor to enter the cells. The inability of zVADfmk to block CD20-mediated cell death was not limited to Ramos cells, but also observed for EBV-transformed B cells and B-CLL lines (unpublished observations). Independent of the concentration applied or duration of the experiment, the percentage of apoptotic cells decreased from ෂ50% to ෂ30%. EM images of such cells showed an appearance strongly resembling that of apoptotic Jurkat cells triggered via MHC class I, 42 and MCF7 cells induced to undergo autophagy by tamoxifen. 37 It might be reasoned that CD20XL-induced apoptosis is specifically mediated by caspase-2, which is in fact poorly inhibited by zVAD-fmk. 43 Caspase-2 was indeed activated in Ramos cells, but to an equal extent regardless of the apoptotic stimulus, and this was fully inhibited by zVADfmk (Eldering et al, manuscript submitted). Hence, it seems more likely that the limited effect of zVAD-fmk on cell survival reflects a bifurcation of the CD20 signal, resulting in inhibition of caspases activated by the mitochondrial pathway, and a sustained activity of an as yet undefined caspase-independent route. In this respect it is interesting that protein kinase C ␦ (PKC␦) has been reported to be able to associate with mitochondria and mediate release of cyt-c, 44 as well as to play a role in activating a lipid scramblase responsible for PS externalization. 45 Very recently, conflicting reports have appeared on the effect of zVAD-fmk on CD20-mediated apoptosis. Our results are compatible with the lack of inhibition of zVAD-fmk in complement-mediated cell death via CD20 in malignant B cells. 46 In contrast, in an evaluation of anti-CD20 homodimers vs monomers to induce apoptosis in several B cell lines, it was stated that zVAD-fmk did in fact prevent CD20-mediated PS exposure. 47 However, in this case the caspase-1 inhibitor YVAD-CHO had a similar inhibitory effect, although in most models inhibition of caspase-1 can clearly be separated from specific inhibition of apoptosis by zVAD. We emphasize that in our experimental system, no such effects of YVAD could be detected (see also Refs 25 and 41) . Furthermore, the early PS exposure we consistently observed by FACS analysis in CD20-stimulated Ramos cells in the presence of zVAD-fmk (see Figure 5 ) was corroborated via morphologic exmination by electron microscopy which also clearly indicated an apoptotic phenotype. Finally, the minimal effect of Bcl-2 overexpression we observed (discussed below) is also consistent with the notion that blocking the apoptotic pathway initiated by mitochondrial cyt-c release and subsequent caspase activation, is not sufficient to prevent CD20-mediated cell death.
Although Bcl-2 can confer protection against a variety of apoptotic stimuli, including many chemotherapeutic drugs, 18 ,19,48,49 CD20XL-induced apoptosis in Ramos cells was maintained despite high Bcl-2 expression. This is in agreement with a recent report that EBV-transformed Ramos cells were still susceptible to CD20XL-induced apoptosis. 38 Although upregulation of Bcl-2 expression is a well known consequence of EBV transformation, the viral LMP-1 gene also mediates other anti-apoptotic and signalling effects. 50, 51 Our experiments with a Ramos transfectant address only the effects of Bcl-2 overexpression, and clearly demonstrate that this confers resistance to CD95-and BCR-mediated apoptosis, but not to CD20XL. Combined with the lack of inhibition by zVADfmk, this clearly suggests the existence of a distinct apoptosis pathway that is independent of active caspases and also independent of the mitochondria. As such a potential mediator, apoptosis inducing factor (AIF) has been considered to be involved in caspase-independent cell death. It is able to induce partial chromatin condensation, large-scale DNA fragmentation and PS exposure, and these phenomena are not inhibited by zVAD-fmk. However, AIF is released from mitochondria and this can be prevented by high Bcl-2 expression. 52, 53 Since CD20XL-induced apoptosis was not inhibited by high Bcl-2 expression, a causal role for AIF seems unlikely. In addition, inhibitors of ceramide synthesis (fumonisin B1, deoxynojirimycin, conduritol B epoxide), 54, 55 nor cyclosporin A, 56, 57 had any effect (data not shown), indicating that CD20XL does not depend on ceramide production or calcineurin and does not act on cyclophylin D to induce apoptosis. A last point concerns the potential contribution of reactive oxygen species (ROS), recently reported to play a role in cell death mediated by combining complement and high levels of rituximab. 46 Under the conditions used in our investigations (5 g/ml rituximab and 50 g/ml crosslinker), we could not detect an inhibitory effect of ROS scavenging by N-acetyl cysteine (NAC; added up to 10 mM) on CD20XL-mediated apoptosis. Higher levels of NAC in fact caused cell death itself, both in Ramos cells and in samples obtained from chronic lymphatic leukemia cells (unpublished observations). We speculate that different experimental conditions (ie crosslinking vs complement, concentration of rituximab used) may contribute to these discrepancies.
The existence of alternative apoptosis pathways has been often alluded to, describing effects of numerous stimuli in varying cell types. Although a uniform genetic and biochemical basis such as described only in recent years for caspasemediated cell death is as yet lacking, a recent report proposed a morphological description. 58 In addition, as we have also shown, currently a discrimination based on the involvement of either death receptors, caspases and/or mitochondria offers a means of identifying potentially relevant novel pathways. 25, 59, 60 Ongoing investigations will determine if and to what extent cellular response mechanisms that may also culminate in apoptosis, such as kinase activation, 42 autophagy 37 or ER stress, 61 are involved in CD20XL and other caspaseindependent forms of cell death.
Since most chemotherapeutic agents require the activation of caspases to induce apoptosis in tumor targets, chemoresistance may be caused by a defect in apoptosis-inducing pathways. Although the clinical relevance is as yet uncertain, a role for caspase-independent apoptosis in the treatment of chemoresistant tumors was recently suggested. 20, 23 Another cause of chemoresistance in hematologic malignancies may be the overexpression of Bcl-2, 48, 62 which has been correlated with poor response to chemotherapy and poor prognosis in hematologic malignancies. [63] [64] [65] [66] Hence, anti-neoplastic agents that act independent of Bcl-2 expression or the activation of caspases, may circumvent chemoresistance of their tumor targets. These aspects are combined in CD20XL-induced apoptosis.
In vivo, Fc␥R-expressing cells may be instrumental for CD20-crosslinking and subsequent apoptosis. 6 Thus, apoptosis could indeed be one of the anti-tumor mechanisms of chimeric anti-CD20 mAbs in vivo. In a study in 31 lymphoma patients with bulky disease, 2 it was demonstrated that the number of prior chemotherapy courses, the number of relapses, resistance to chemotherapy, prior aggressive therapy or prior anthracyclin therapy, were not correlated to the response to anti-CD20-therapy. Furthermore, in low grade lymphoma patients treated with chimeric anti-CD20 mAbs, 1 baseline peripheral blood Bcl-2 negativity was correlated with a lower response to CD20 therapy, indicating that Bcl-2-positive tumors were sensitive to CD20 therapy. Thus, these clinical data are consistent with our in vitro results suggesting that CD20XL may induce apoptosis in tumor cells that acquired resistance to chemotherapeutic agents.
In conclusion, CD20XL can induce apoptosis independently of mitochondria or caspase activation. Therefore, treatment via CD20XL is likely to circumvent important causes of chemoresistance. This may explain the favorable clinical results of chimeric CD20 mAbs in chemoresistant lymphomas.
